Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.78 |
| ▸ | RAB9A | P51151 | 7/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15657407 | 0.97 | SMN1; SMN2 (0.73) | SMN1; SMN2RAB9AALDH1A1HPGDNPSR1 | |
| SCHEMBL15656341 | 0.97 | SMN1; SMN2 (0.73) | SMN1; SMN2RAB9AALDH1A1HPGDNPSR1 | |
| SCHEMBL15679959 | 0.89 | RAB9A (0.81) | SMN1; SMN2RAB9AALDH1A1HPGDNPSR1 | |
| SCHEMBL1327631 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2RAB9AALDH1A1HPGDNPSR1 | |
| SCHEMBL28836113 | 0.86 | RAB9A (0.77) | SMN1; SMN2RAB9AALDH1A1HPGDNPSR1 | |
| SCHEMBL15656858 | 0.85 | RAB9A (0.74) | SMN1; SMN2RAB9AALDH1A1HPGDNPSR1 | |
| SCHEMBL10223891 | 0.85 | SMN1; SMN2 (0.76) | SMN1; SMN2RAB9AALDH1A1HPGDNPSR1 | |
| SCHEMBL892990 | 0.85 | SMN1; SMN2 (0.76) | SMN1; SMN2RAB9AALDH1A1HPGDNPSR1 | |
| SCHEMBL1575054 | 0.85 | RAB9A (0.69) | SMN1; SMN2RAB9AALDH1A1HPGDNPSR1 | |
| SCHEMBL289112 | 0.85 | SMN1; SMN2 (0.93) | SMN1; SMN2RAB9AALDH1A1HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114990587-B | Electrochemical synthesis method of thiazole compound | 华南理工大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-114990587-A | Electrochemical synthesis method of thiazole compound | 华南理工大学 | 2022-09-02 | — | — | CN | disclosed |
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2016-05-26 | — | — | US | disclosed |
| WO-2016073847-A2 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-05-12 | — | — | WO | disclosed |
| US-8927551-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140121249-A1 | ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2014-05-01 | — | — | US | disclosed |
| EP-2432771-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110028482-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2010135360-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1214292-B1 | TYROSINE DERIVATIVES | GENENTECH INC (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2005113003-A2 | METHOD FOR AUGMENTING B CELL DEPLETION | GENENTECH, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | SREBF1, SREBF2, BPTF | SMN1; SMN2 3141/4885RAB9A 2184/4885ALDH1A1 2475/4885 |
| US-20140121249-A1 | ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE | CLPP, ELANE, NOD2 | SMN1; SMN2 3558/4885RAB9A 4089/4885ALDH1A1 1628/4885 |
| US-20110028482-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | SMN1; SMN2 4142/4885RAB9A 1459/4885ALDH1A1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.